{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:27:18Z","timestamp":1764872838529},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,2,21]],"date-time":"2005-02-21T00:00:00Z","timestamp":1108944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The pathophysiology of the myelodysplastic syndromes (MDS) involves disturbed regulation of angiogenesis, apoptosis, proliferation and differentiation as well as immune surveillance. Increasing data suggest that sirolimus might affect these pathways positively, thus being of possible therapeutic benefit in patients with this disease. Nineteen patients (<jats:italic>n<\/jats:italic>\u2003=\u200319) with a median age of 72\u2003years (range 54\u201380\u2003years) diagnosed with MDS received sirolimus orally with a target blood concentration of 3\u201312\u2003ng\/ml. Sirolimus was administered for a median of 3\u00b77\u2003months (range 0\u00b73\u201311\u2003months). Three patients [1\u2003\u00d7\u2003refractory anaemia with excess blasts (RAEB)\u20102, 1\u2003\u00d7\u2003RAEB\u20101, 1\u2003\u00d7\u2003refractory cytopenia with multilineage dysplasia] showed either a major (1\u2003\u00d7\u2003platelet, 1\u2003\u00d7\u2003neutrophil) or a minor (1\u2003\u00d7\u2003erythroid, 2\u2003\u00d7\u2003platelet) haematological response according to International Working Group criteria. Major side\u2010effects were hyperlipidaemia (<jats:italic>n<\/jats:italic>\u2003=\u20034), stomatitis (<jats:italic>n<\/jats:italic>\u2003=\u20033), thrombocytopenia (<jats:italic>n<\/jats:italic>\u2003=\u20032) and urinary tract infection (<jats:italic>n<\/jats:italic>\u2003=\u20031). These data suggest that sirolimus has activity in a subset of patients with more advanced MDS.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05360.x","type":"journal-article","created":{"date-parts":[[2005,2,21]],"date-time":"2005-02-21T12:55:49Z","timestamp":1108990549000},"page":"625-630","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Activity of sirolimus in patients with myelodysplastic syndrome \u2013 results of a pilot study"],"prefix":"10.1111","volume":"128","author":[{"given":"U.","family":"Platzbecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Haase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Voigtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Schleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Leopold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Orth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1427"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/152581602753448586"},{"key":"e_1_2_10_4_1","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson B.D.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034447.02535.D5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-128"},{"key":"e_1_2_10_7_1","first-page":"886","article-title":"Rapamycin causes poorly reversible inhibition of mTOR and induces p53\u2010independent apoptosis in human rhabdomyosarcoma cells","volume":"59","author":"Hosoi H.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1054\/drup.2002.0227"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.3.9.981"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00551.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200205270-00008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-3-200208060-00007"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000118462.22970.BE"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20026"},{"key":"e_1_2_10_15_1","article-title":"Anti\u2010leukemic activity of rapamycin in acute myeloid leukemia","author":"Recher C.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4326"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03551.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3429"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00626-9"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03204.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05360.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05360.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:31:05Z","timestamp":1697416265000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05360.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,21]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05360.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05360.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,21]]},"assertion":[{"value":"2005-02-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}